腫瘍治療薬の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Large Therapy Area with Varying Unmet Needs Across Indications 5
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation 5
2.3 A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets 5
3 The Case for Innovation in the Oncology Market 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 14
4.1.3 Pathophysiology 15
4.1.4 Diagnosis 21
4.1.5 Prognosis and Disease Staging 22
4.2 Treatment Options 24
4.2.1 Surgery and Radiation Therapy 24
4.2.2 Chemotherapy 27
4.2.3 Hormonal Therapies 28
4.2.4 Targeted Therapies 29
4.3 Overview of Marketed Products for Oncology 30
4.4 Current Unmet Needs across the Oncology Markets 32
5 Assessment of Pipeline Product Innovation 34
5.1 Oncology Pipeline by Phase, Molecule Type and Molecular Target 35
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family 38
5.3 First-in-Class and Versatile Pipeline Programs 38
5.3.1 First-in-Class Oncology Products by Phase, Molecule Type and Molecular Target 40
5.3.2 Versatility of First-in-Class Pipeline Products 43
6 Signaling Pathways, Disease-Causing Mutations and Versatile First-in-Class Molecular Target Integration 54
6.1 The Complexity of Signaling Networks in Oncology 54
6.2 Signaling Pathways, Disease-Causing Mutations and Versatile First-in-Class Molecular Target Integration 54
6.3 Versatile First-in-Class Target Matrix Assessment 56
7 Versatile First-in-Class Target Assessment 62
7.1 Pipeline Programs that Target Fibroblast Growth Factor Receptor-3 62
7.2 Pipeline Programs that Target Human Epidermal Growth Factor Receptors-3 and -4 65
7.3 Pipeline Programs that Target Phosphoinositide 3-Kinase Alpha 68
7.4 Pipeline Programs that Target Akt1, 2 and 3 71
7.5 Pipeline Programs that Target Telomerase Reverse Transcriptase 75
7.6 Pipeline Programs that Target Heat Shock Protein 90 77
7.7 Pipeline Programs that Target Focal Adhesion Kinase 80
7.8 Pipeline Programs that Target DNA-Dependent Protein Kinase 82
7.9 Pipeline Programs that Target Programmed Death Ligand-1 83
7.10 Conclusion 86
8 Deals and Strategic Consolidations 87
8.1 Industry-Wide First-in-Class Deals 87
8.2 Licensing Deals 88
8.3 Co-development Deals 95
9 Appendix 100
9.1 Abbreviations 100
9.2 References 100
9.2.1 Main 100
9.3 Contact Us 108
9.4 Disclaimer 108